Literature DB >> 23979089

Severe early-onset colitis revealing mevalonate kinase deficiency.

Michael Levy1, Alina Arion, Dominique Berrebi, Laurence Cuisset, Corinne Jeanne-Pasquier, Brigitte Bader-Meunier, Camille Jung.   

Abstract

Hyperimmunoglobulinemia D is the less severe form of mevalonate kinase deficiency (MKD) caused by recessive inherited mutation in the mevalonate kinase gene. Hyperimmunoglobulinemia D is characterized by febrile attacks, often associated with transient digestive manifestations, such as abdominal pain, diarrhea, and vomiting. Here we report for the first time 2 patients with MKD revealed by severe neonatal colitis. Both patients had chronic bloody diarrhea and failure to thrive; 1 patient since the age of 1 month and the other since the age of 12 days. Total parenteral nutrition was required. A marked elevation of acute phase reactants was present, and no evidence of infection was found. In patient 1, ileocolonoscopy revealed ulcerative colitis at the age of 5 months. Patient 2 suffered from enterocolitis and shock, associated with multiple bowel adhesions at age 5 weeks; the rectosigmoidoscopy showed aphtoid lesions of the sigmoid colon. Pathologic findings of colonic biopsies revealed a dense polymorph inflammatory infiltrate associated with deep ulcerations. Febrile attacks occurred 2 months after the onset of digestive symptoms in patient 1, and at onset of disease in patient 2. Genomic sequencing of the mevalonate kinase gene revealed compound heterozygous mutations in both patients. Anti-interleukin-1 agent produced long-term remission of all digestive features and laboratory parameters. This report emphasizes that MKD may be the cause of severe early-onset inflammatory colitis, and must be considered by physicians, even in the absence of fever, after ruling out infections. Anti-interleukin-1 therapy may result in a dramatic improvement of MKD-related inflammatory bowel disease.

Entities:  

Keywords:  Mevalonate kinase deficiency; anti-interleukin-1; colitis; infant

Mesh:

Substances:

Year:  2013        PMID: 23979089     DOI: 10.1542/peds.2012-3344

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  26 in total

Review 1.  Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience.

Authors:  Svetlana Kostjukovits; Liisa Kalliokoski; Kaisu Antila; Matti Korppi
Journal:  Eur J Pediatr       Date:  2015-02-27       Impact factor: 3.183

Review 2.  Mechanisms and function of autophagy in intestinal disease.

Authors:  Kara G Lassen; Ramnik J Xavier
Journal:  Autophagy       Date:  2018-01-29       Impact factor: 16.016

3.  Mevalonate kinase deficiency presenting as recurrent rectal abscesses and perianal fistulae.

Authors:  Kara Dunn; Brad Pasternak; Judith R Kelsen; Kathleen E Sullivan; Noor Dawany; Benjamin L Wright
Journal:  Ann Allergy Asthma Immunol       Date:  2017-12-28       Impact factor: 6.347

4.  Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.

Authors:  Neil E McCarthy; Charlotte R Hedin; Theodore J Sanders; Protima Amon; Inva Hoti; Ibrahim Ayada; Vidya Baji; Edward M Giles; Martha Wildemann; Zora Bashir; Kevin Whelan; Ian Sanderson; James O Lindsay; Andrew J Stagg
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

Review 5.  Linking Genetic Diagnosis to Therapeutic Approach in Very Early Onset Inflammatory Bowel Disease: Pharmacologic Considerations.

Authors:  Anne E Levine; Hengqi B Zheng; David L Suskind
Journal:  Paediatr Drugs       Date:  2022-04-25       Impact factor: 3.022

Review 6.  Monogenic inflammatory bowel disease-genetic variants, functional mechanisms and personalised medicine in clinical practice.

Authors:  Aline Azabdaftari; Kelsey D J Jones; Jochen Kammermeier; Holm H Uhlig
Journal:  Hum Genet       Date:  2022-06-28       Impact factor: 4.132

Review 7.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 8.  Genetics of inflammatory bowel disease from multifactorial to monogenic forms.

Authors:  Anna Monica Bianco; Martina Girardelli; Alberto Tommasini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

Review 9.  A Systematic Review of Monogenic Inflammatory Bowel Disease.

Authors:  Ryusuke Nambu; Neil Warner; Daniel J Mulder; Daniel Kotlarz; Dermot P B McGovern; Judy Cho; Christoph Klein; Scott B Snapper; Anne M Griffiths; Itaru Iwama; Aleixo M Muise
Journal:  Clin Gastroenterol Hepatol       Date:  2021-03-18       Impact factor: 11.382

Review 10.  Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.

Authors:  Jodie Ouahed; Elizabeth Spencer; Daniel Kotlarz; Dror S Shouval; Matthew Kowalik; Kaiyue Peng; Michael Field; Leslie Grushkin-Lerner; Sung-Yun Pai; Athos Bousvaros; Judy Cho; Carmen Argmann; Eric Schadt; Dermot P B Mcgovern; Michal Mokry; Edward Nieuwenhuis; Hans Clevers; Fiona Powrie; Holm Uhlig; Christoph Klein; Aleixo Muise; Marla Dubinsky; Scott B Snapper
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.